Zidovudine removal during plasma exchange.
Pharmacokinetics of zidovudine (azidothymidine, AZT) were investigated after oral administration (300 mg every 8 hours) in a human immunodeficiency virus seropositive patient who was also treated with plasma exchange (60 ml/kg). Plasma AZT concentrations were measured using high performance liquid chromatography assay. Plasma exchange clearances reached 1-3.8% of the total clearance. The fraction of AZT removed from separated plasma accounted for only 1% of the administered dose. The contribution of plasma exchange to the elimination of AZT appears to be negligible. Solely on the basis of AZT pharmacokinetic data, no particular dose adjustment appears to be necessary in patients treated with multiple plasma exchanges.
Fauvelle
F
F
Service de Pharmacie Clinique, CHI Montfermeil, France.
Leon
A
A
Petitjean
O
O
Guillevin
L
L
D000328:Adult; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D014657:Vasculitis / Q000150:complications / Q000628:therapy; D015215:Zidovudine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D015215:Zidovudine